PT - JOURNAL ARTICLE ED - , TI - Bazedoxifene for HRT? AID - 10.1136/dtb.2017.4.0466 DP - 2017 Apr 01 TA - Drug and Therapeutics Bulletin PG - 42--44 VI - 55 IP - 4 4099 - http://dtb.bmj.com/content/55/4/42.short 4100 - http://dtb.bmj.com/content/55/4/42.full SO - Drug Ther Bull2017 Apr 01; 55 AB - Duavive (Pfizer) is a modified-release formulation of conjugated oestrogens plus bazedoxifene acetate (a selective oestrogen receptor modulator). It is licensed for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestogen-containing therapy is not appropriate.1,2 It was licensed by the European Medicines Agency (EMA) in 2014 and launched in the UK in July 2016.1,3 Here, we review the evidence on efficacy and safety of conjugated oestrogens/bazedoxifene and consider its place in the management of symptoms associated with the menopause.